1,6-anhydro-α-D-glucofuranose

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氧唑烯
• 英文名称: 1,6-anhydro-α-D-glucofuranose
• 英文别名: 6-deoxy-1,4-anhydrosorbitol；(2R,3R,4S)-2-[(1R)-1-hydroxyethyl]oxolane-3,4-diol
• 化学式: C₆H₁₂O₄
• 分子量: 148.159
• InChiKey: FTUNCEVUAPNORM-JGWLITMVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  69.9
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  1,2,3,4,6-penta-O-trimethylsilyl-α-D-glucopyranose 在 三(五氟苯基)硼烷 、 甲醇 、 水 作用下， 以 二氯甲烷-D2 为溶剂， 反应 3.5h， 以22%的产率得到1,6-anhydro-α-D-glucofuranose
  参考文献：
  名称：

  利用聚（甲基氢硅氧烷）的反应性，以减少生物量并将其环化为高价值产品

  摘要：

  已对聚（甲基氢硅氧烷）（PMHS）使用催化三（五氟苯基）硼烷（BCF）还原并随后环化碳水化合物底物的能力进行了研究。本文的工作是第一个报道的实例，该实例是利用氢化硅氧烷还原剂将单糖直接转化为1,4-脱水和2,5-脱水的产物。PMHS由有机硅行业的废品生产而成，使其成为传统氢硅烷还原剂的绿色替代品。因此，这项工作有助于实现在精细化学品生产中利用可再生原料的目标。

  DOI：

  10.1039/c9gc00705a

文献信息

• Compositions and methods for ophthalmic and/or other applications
  申请人：The Johns Hopkins University

  公开号：US10646437B2

  公开（公告）日：2020-05-12

  Particles, compositions, and methods that aid particle transport in mucus are provided. The particles, compositions, and methods may be used, in some instances, for ophthalmic and/or other applications. In some embodiments, the compositions and methods may involve modifying the surface coatings of particles, such as particles of pharmaceutical agents that have a low aqueous solubility. Such compositions and methods can be used to achieve efficient transport of particles of pharmaceutical agents though mucus barriers in the body for a wide spectrum of applications, including drug delivery, imaging, and diagnostic applications. In certain embodiments, a pharmaceutical composition including such particles is well-suited for ophthalmic applications, and may be used for delivering pharmaceutical agents to the front of the eye and/or the back of the eye.

  本文提供了有助于颗粒在粘液中传输的颗粒、组合物和方法。这些微粒、组合物和方法在某些情况下可用于眼科和/或其他应用。在某些实施方案中，这些组合物和方法可能涉及颗粒表面涂层的改性，例如水溶性较低的药剂颗粒。此类组合物和方法可用于实现药剂颗粒通过体内粘液屏障的高效运输，应用范围广泛，包括药物输送、成像和诊断应用。在某些实施方案中，包括此类微粒的药物组合物非常适合眼科应用，可用于将药剂输送到眼球前部和/或眼球后部。
• Nanocrystals, compositions, and methods that aid particle transport in mucus
  申请人：The Johns Hopkins University

  公开号：US10736854B2

  公开（公告）日：2020-08-11

  Nanocrystals, compositions, and methods that aid particle transport in mucus are provided. In some embodiments, the compositions and methods involve making mucus-penetrating particles (MPP) without any polymeric carriers, or with minimal use of polymeric carriers. The compositions and methods may include, in some embodiments, modifying the surface coatings of particles formed of pharmaceutical agents that have a low water solubility. Such methods and compositions can be used to achieve efficient transport of particles of pharmaceutical agents though mucus barriers in the body for a wide spectrum of applications, including drug delivery, imaging, and diagnostic applications. In certain embodiments, a pharmaceutical composition including such particles is well-suited for administration routes involving the particles passing through a mucosal barrier.

  本文提供了有助于颗粒在粘液中传输的纳米晶体、组合物和方法。在某些实施方案中，这些组合物和方法涉及在不使用任何聚合物载体或尽量少使用聚合物载体的情况下制造粘液渗透粒子（MPP）。在某些实施方案中，组合物和方法可包括修改由水溶性低的药剂形成的颗粒的表面涂层。这种方法和组合物可用于实现药剂颗粒通过体内粘液屏障的高效运输，应用范围广泛，包括药物输送、成像和诊断应用。在某些实施方案中，包括此类颗粒的药物组合物非常适合于颗粒通过粘膜屏障的给药途径。
• Nanostructured lipid carriers and stable emulsions and uses thereof
  申请人：Infectious Disease Research Institute

  公开号：US11141377B2

  公开（公告）日：2021-10-12

  Provided herein are nanostructured lipid carrier compositions, and methods of making and using thereof. The compositions comprise a nanostructured lipid carrier (NLC), where the NLC comprises an oil core comprising a mixture of a liquid phase lipid and a solid phase lipid, a cationic lipid, a sorbitan ester, and a hydrophilic surfactant, and optionally a bioactive agent. The bioactive agent can be associated with the NLC. The compositions are capable of delivery of a biomolecule to a cell for the generation of an immune response, for example, for vaccine, therapeutic, or diagnostic uses. Compositions and methods related to making the compositions and using the compositions for stimulating an immune response are also provided.

  本文提供了纳米结构脂质载体组合物及其制造和使用方法。这些组合物包括纳米结构脂质载体（NLC），其中 NLC 包括由液相脂质和固相脂质、阳离子脂质、山梨醇酯和亲水性表面活性剂混合物组成的油核，以及可选的生物活性剂。生物活性剂可与 NLC 联用。这些组合物能够将生物分子输送到细胞中以产生免疫反应，例如用于疫苗、治疗或诊断。此外，还提供了与制造组合物和使用组合物刺激免疫反应有关的组合物和方法。
• NANOCRYSTALS, COMPOSITIONS, AND METHODS THAT AID PARTICLE TRANSPORT IN MUCUS
  申请人：Kala Pharmaceuticals, Inc.

  公开号：US20170128378A1

  公开（公告）日：2017-05-11

  Nanocrystals, compositions, and methods that aid particle transport in mucus are provided. In some embodiments, the compositions and methods involve making mucus-penetrating particles (MPP) without any polymeric carriers, or with minimal use of polymeric carriers. The compositions and methods may include, in some embodiments, modifying the surface coatings of particles formed of pharmaceutical agents that have a low water solubility. Such methods and compositions can be used to achieve efficient transport of particles of pharmaceutical agents though mucus barriers in the body for a wide spectrum of applications, including drug delivery, imaging, and diagnostic applications. In certain embodiments, a pharmaceutical composition including such particles is well-suited for administration routes involving the particles passing through a mucosal barrier.
• COMPOSITIONS AND METHODS FOR OPHTHALMIC AND/OR OTHER APPLICATIONS
  申请人：The Johns Hopkins University

  公开号：US20180064641A1

  公开（公告）日：2018-03-08

  Particles, compositions, and methods that aid particle transport in mucus are provided. The particles, compositions, and methods may be used, in some instances, for ophthalmic and/or other applications. In some embodiments, the compositions and methods may involve modifying the surface coatings of particles, such as particles of pharmaceutical agents that have a low aqueous solubility. Such compositions and methods can be used to achieve efficient transport of particles of pharmaceutical agents though mucus barriers in the body for a wide spectrum of applications, including drug delivery, imaging, and diagnostic applications. In certain embodiments, a pharmaceutical composition including such particles is well-suited for ophthalmic applications, and may be used for delivering pharmaceutical agents to the front of the eye and/or the back of the eye.